EI
ALT icon

EAM Investors’s Altimmune ALT Stock Holding History

EAM Investors’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-56,716
Closed -$638K – 242
2023
Q4 		$638K Buy
+56,716
New +$237K 0.11% 207
2022
Q4 		– Sell
-205,167
Closed -$2.62M – 253
2022
Q3 		$2.62M Buy
205,167
+10,896
+6% +$161K 0.57% 53
2022
Q2 		$2.27M Buy
+194,271
New +$1.2M 0.55% 58

Other funds holding ALT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

EAM Investors's ALT Position: Q1 2024 in Review

EAM Investors sold out of Altimmune (ALT) in Q1 2024, closing a stake of 56,716 shares — an estimated $638K sold.

EAM Investors first reported a position in ALT in Q2 2022 and held it in 3 quarters. The position peaked at $2.62M in Q3 2022. 172 funds tracked by Wall St. Rank hold ALT as of Q1 2024.

  • EAM Investors reported no remaining Altimmune position as of Q1 2024 after selling out during the quarter.
  • EAM Investors sold 56,716 Altimmune shares in Q1 2024, an estimated $638K.
  • EAM Investors first reported a position in Altimmune in Q2 2022 and held it in 3 quarters.
  • EAM Investors's Altimmune position peaked at $2.62M in Q3 2022.
  • 172 funds tracked by Wall St. Rank held Altimmune as of Q1 2024.

Based on EAM Investors's 13F filing for Q1 2024, filed 13 May 2024.